|
|
|
| BoB@JPM: Tom Chalberg, Ph.D., Genascence | Join Business of Biotech’s Matt Pillar and Ben Comer as they dive into the future of gene therapy with Dr. Tom Chalberg, CEO of Genascence. The discussion explores the shift from rare disease treatments to common conditions like osteoarthritis, the challenges of delivery and regulation, and Genascence’s partnership strategy. Tune in for an insightful look at the changing landscape of ATMPS! |
|
|
|
|
Andrey Dobry was a Silicon Valley tech leader before deciding that the best way to use AI to transform lives was through drug development. |
|
|
|
| The Scoop On The SCOPE Summit | From industry partnerships to patient recruitment to proprietary data, SCOPE 2025 was packed with informational sessions. |
|
|
|
| Optimizing Bioprocesses Using Functional DOE | Combining Functional Design of Experiments (DOE) with traditional DOE methods enhances process optimization by capturing dynamic, time-based variations in cell culture systems. |
|
|
|
|
